Alvine Pharmaceuticals Obtains $21,500,000 Series A Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=11c4a41f-5a6f-4641-8f8a-c4d8ab55bbe7&Preview=1 -
Date
9/15/2009 -
Company Name
Alvine Pharmaceuticals -
Mailing Address
75 Shoreway Rd. San Carlos, CA 94070 -
Company Description
Alvine Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutics for the treatment of Celiac sprue. -
Website
http://www.alvinepharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$21,500,000 -
Transaction Round
Series A -
Proceeds Purposes
This funding will support the continued development of ALV003 as an innovative protease therapy for the treatment of celiac disease, and further our goal to be the leading company in this space. -
M&A Terms
-
Venture Investor
Panorama Capital -
Venture Investor
InterWest Partners -
Venture Investor
Prospect Venture Partners -
Venture Investor
Sofinnova Ventures -
Venture Investor
Flagship Ventures
